Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility

J Clin Oncol. 2014 Oct 10;32(29):3207-9. doi: 10.1200/JCO.2014.57.6132. Epub 2014 Sep 8.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics*
  • Class I Phosphatidylinositol 3-Kinases
  • Female
  • Humans
  • Mutation*
  • Phosphatidylinositol 3-Kinases / genetics*
  • Receptor, ErbB-2 / antagonists & inhibitors*

Substances

  • Phosphatidylinositol 3-Kinases
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CA protein, human
  • ERBB2 protein, human
  • Receptor, ErbB-2